Popit company news

Open position: Digital Operations Market Manager

Are you a self-driven professional with a strong track record in getting things done? Do you have a flair for content creation and analytics? Would you be interested in launching a unique digital health solution on new markets? Well look no further and get in touch!

Popit is a pioneering Finnish startup and we make medication digital. By doing so we improve medication adherence and help patients get the best possible medical treatment outcome. We’re big on making things happen and small on hierarchy. Popit works with the world’s largest pharmaceutical companies in Europe and Japan and our goal is to make a positive impact on the treatment of as many patients as possible. We support the United Nations Development Goal number 3 – Good Health and Wellbeing.

We are looking for a creative and analytical Digital Operations Market Manager (DOMM) to work with our pharma customers in introducing Popit to patients on new markets. The person we have in mind is a great communicator who can coordinate a project efficiently. S/he also knows how to create content, interpret data and draw conclusions from it and be a creative problem solver at heart.

What you would be doing:

  • Influence and create patient and healthcare professional (HCP) facing materials for new markets (such as onboarding materials, ads, flyers, video tutorials, webinars, blog posts, etc.).
  • Coordinate with PMs of respective markets to provide sales and onboarding materials, localize content and gather feedback on the content effectiveness.
  • Provide product training and onboarding support to local pharma customer reps and
  • Analyze and report the performance and success of rolled out campaigns and materials.
  • Data points to use: pharma customer feedback, patient feedback, Popit Solution data, Anonymous app data analytics.
  • Identify new marketing strategies and channels to enable growth.

Ideally, you have

  • 4+ years experience in project management/coordination
  • Hands on experience with Excel and analytics tools
  • Hands on experience with graphics tools, such as InDesign, Illustrator and Photoshop (or similar).
  • Excellent communication and interpersonal skills with a knack for understanding communication in different cultures
  • Creative and persistent problem-solving approach and customer-centric thinking
  • Entrepreneurial spirit
  • Desire to learn new things and not be afraid to go outside your comfort zone.
  • Professional fluency in English. Other languages – especially Japanese – considered a plus
  • Experience from pharma or health tech industry considered a plus

We offer

  • A challenging key role in a truly international company.
  • An opportunity to make a real impact on the lives of patients.
  • A possibility to grow with the company and build this into a team lead role. You get to influence the direction.
  • Competitive salary.
  • Work flexibility – We expect to see you at our office frequently (when things normalize, of course), but you can also work from home.
  • We’re still a company that’s growing up, so don’t expect a La Pavoni espresso machine or weekly fruit basket deliveries. They’re coming somewhere down the line, but right now we’re focusing on doing the right things for the business. We have two excellent restaurants in the building though and you do get lunch benefits. Oh and a free gym too, so you don’t have to spend time commuting to get those rock-hard abs :)

Employment Type

Full-time

How to apply

Send your CV and optional cover letter to timo a popit io

or apply through LinkedIn.

 

Popit and Ashfield Engage Partner To Improve Patient Adherence

Ashfield Engage and Popit partner to improve patient adherence through supplemental real-time personalized support.

Ashfield Engage, part of UDG Healthcare plc, today announces it has partnered with Popit, a digital health company, to improve patient adherence in oral solid dosage (OSD) treatments and advance supplemental personalized patient support.

The collaboration brings together Popit’s novel monitoring technology, and Ashfield Engage’s patient support programs, to proactively respond to patients’ needs and tailor their reminders accordingly.

The Popit Sense™ device is attached to a pill sheet and uses patented technology to monitor missed doses and send alerts to patients via a smartphone app. The data is also transmitted to healthcare providers and support partners such as Ashfield Engage. Now enriched with this real-time data, Ashfield Engage can easily identify which patients require extra support.

As well as providing support through the app, Ashfield Engage will leverage its expert call center teams to reach out to patients to discuss any challenges with their medication.

We can engage with patients in a way that was previously not possible.

Ian Riches, Global Vice President, Patient Solutions at Ashfield Engage, explained:

“Prior to Popit’s technology, a large group of OSD patients were not getting the support they needed. While the majority of patients are adherent, those with a need for support can now be quickly identified and we can engage with them in a way that was previously not possible, which is really exciting.

“While typically patient data is only collected up to the point of prescription, we can now support patients throughout their treatment in real-time. By partnering with Popit we have a digital solution that enables rapid, personalized support to increase patient adherence and significantly improve patients’ health and wellbeing in the long term.”

Popit Sense technology is already being leveraged by many large pharmaceutical organizations, including Pfizer, Almirall and Novartis.

We see this as a really important step towards building better, more connected healthcare solutions that truly benefit patients’ health.

Timo Heikkilä, COO and Co-Founder of Popit, added: “Our solution provides a wealth of invaluable data for healthcare providers, and pharmaceutical organizations and we have seen excellent results following its adoption.

“By partnering with Ashfield Engage, we can now advance that service, and provide not only the data, but the direct follow up support to those patients in need. We are thrilled about this collaboration and look forward to supporting the large patient population reliant on OSD treatments. We see this as a really important step towards building better, more connected healthcare solutions that truly benefit patients’ health.”

To find out more about how Ashfield Engage and Popit Sense can benefit your organization, your product and your patients, visit: https://ashfieldengage.com/

To learn more about Popit, visit: https://popit.io/.

Contact Information

Lara Lovenbury, ramarketing | lara@ramarketingpr.com | +44 773 268 1275

About Popit

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitalizing medication, a major opportunity that benefits patients, patient support programs, healthcare payors and the pharmaceutical industry. Popit works with the world’s leading pharmaceutical companies in executing against this vision.

For more information, go to https://popit.io/

Popit Media contact: 

Timo Heikkilä
Co-founder & COO
Phone: +358 50 487 3728
timo@popit.io

About Ashfield

Ashfield, part of UDG, is an integrated healthcare services partner, offering a breadth of services across strategic consulting, benchmarking, commercialization, customer engagement, events, marketing and communications.

Ashfield comprises of three clearly defined, integrated business units: Ashfield Advisory, Ashfield Engage and Ashfield Health. Together, the Ashfield team uses imagination, strategy and action to redefine and deepen client partnerships, reimagine health and improve lives.

Ashfield   has   carefully   curated   its   business   through   the   acquisition   of   22 companies and is committed to offering streamlined services to best meet its clients’ needs. With a presence in more than 50 countries, over 7,000 employees strive to provide best-in-class service for more than 300 clients, including the top 30 global pharmaceutical companies.

For more information, go to www.oneashfield.com

About Ashfield Engage

Ashfield Engage, part of UDG Healthcare plc, is an expert, global partner in customer strategy and execution. Ashfield Engage helps clients connect with all healthcare audiences to ensure people get knowledge, support and medicines when and where they need them. As experts in strategic engagement, Ashfield Engage creates personalized, impactful experiences, across all channels. Every program is underpinned by human connections, omnichannel engagement and adaptive analytics.

Ashfield Engage has over 20 years’ experience with a team of over 5,000 employees, delivering services in more than 50 countries. Offering services across Medical Affairs, Market Access, Commercial, Patient Solutions and Event Experiences, Ashfield Engage helps its clients to engage with their stakeholders across the whole commercialization journey. Under the Ashfield umbrella, Ashfield Engage sits alongside Ashfield Advisory and Ashfield Health.

For more information, go to https://ashfieldengage.com/

Popit And Almirall Start Offering New Support Tool To Help Psoriasis Patients

The Finnish digital health startup launches together with the biopharmaceutical company focused on skin health, first in The Netherlands.

HELSINKI, FINLAND / BARCELONA, SPAIN – NOVEMBER 12th, 2020

Finnish digital health startup Popit and Almirall, a global biopharmaceutical company focused on skin health have started a collaboration to provide a novel support solution for patients with psoriasis. Popit’s innovative solution is available for patients using the Skilarence® (Dimethyl fumarate) medication, used for treatment of moderate-to-severe plaque psoriasis. The solution improves medication adherence and offers support for the patient. The partnership has started with the first patients already using Popit in The Netherlands.

Psoriasis is a chronic, non-contagious skin disease with symptoms that include clearly defined red patches (“plaques”), scaly skin and often itching. It is estimated that 125 million people worldwide – or 2 to 3 % of the population – have psoriasis1. The condition has a profound impact on patients: nearly 60 % of people with psoriasis reported their disease to be a large problem in their everyday life2.

Skilarence® (Dimethyl fumarate) is a systemic treatment taken orally for psoriasis3. As with all medications, if patients are not taking it according to guidance, they also do not receive the best possible treatment outcomes. Popit helps patients stay on track with the treatment and gain access to tailor-made content on their therapy.

The innovative solution consists of a unique device that automatically tracks when a medication is taken, as well as an accompanying app that reminds only if a dose has been missed. The patient also receives useful support messages and psoriasis content tailored specifically for them. Popit has been clinically validated to significantly reduce missed doses4 and is already used by some of the largest pharmaceutical companies in the world with great results.

In the words of Francesca Wuttke, Chief Digital Officer of Almirall:

We are pleased to be collaborating with Popit to bring novel adherence and engagement solutions to patients with psoriasis. As a result of this partnership we are able to provide a new patient experience through digital psoriasis treatment to inform, educate, manage expectations, and motivate our patients. Making our medicines connected is a huge leap for patients and the industry and we’re excited to be doing it with Popit”.

Teemu Piirainen, Popit’s CEO weighs in:

There is a great need to improve medication adherence and patient support in psoriasis care. Popit can really help in this by tackling some of the most common causes for why doses are missed, which include forgetting the daily doses and insufficient awareness of how missed doses impact treatment outcomes. Additionally, the patient might face quite practical challenges with their treatment, like up-titration or predetermined changes in product strength, which may not always be easy to master. Popit supports the patient with these challenges.

 

About Popit:

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitizing medication, a major opportunity that offers benefits for patients, healthcare payors and pharmaceutical companies. Popit works with the world’s leading pharmaceutical companies.

For more information, please visit popit.io

 

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (BME: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

 

Almirall media contact:

Communications Agency: Tinkle
Pilar Colomer
pcolomer@tinkle.es
Phone: (+34) 93 93 545 0861

Almirall Communications contact:
Francesca Wuttke
francesca.wuttke@almirall.com

Popit Media contact: 

Timo Heikkilä
Co-founder & COO
Phone: +358 50 487 3728
timo@popit.io

References:

  1. Psoriasis.org (https://www.psoriasis.org/psoriasis-statistics/)
  2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.
  3. European Medicines Agency (https://www.ema.europa.eu/en/documents/overview/skilarence-epar-summary-public_en.pdf)
  4. DOI: 10.15761/COGRM.1000217

Popit Develops Research Tool for COVID-19 Treatment

The telehealth startup’s platform streamlines the global effort of finding a treatment for COVID-19.

HELSINKI, FINLAND, MAY 7TH, 2020

Finnish MedTech and telehealth startup Popit has released a research extension that makes its platform an efficient tool for finding a treatment for COVID-19. The new enhancement called POPIT INSIGHTS™ provides unprecedented real-time data on how the medications being researched are taken. At the same time data quality is improved, since patients in the study take their medications more consistently thanks to Popit’s clinically validated adherence improvement impact. The new tool basically reduces missed pills and makes studies faster. Popit already has partners for the new product and is kicking off with first studies.

As the COVID-19 pandemic rages on, the world’s scientific community has come together in an exceptional way. New studies to chart out possible treatments are constantly starting. Today, on May 7th, there are nearly 800 listed COVID-19 studies either starting or already active around the globe.1

Getting patients to take the study medications in a timely manner is highly important for research success.

On average each study has over 500 patients, biggest ones having over 40 000 participants. Getting all these patients to take the study medications in a timely manner is highly important for research success – and also for the patients themselves to benefit from the treatment. Considering the gravity of the matter it is surprising that only 43% of study patients may be adherent.2 Reminding the rest of the patients to take their medications and simply having data on if those medications were actually taken or missed have not been a part of the researchers’ toolbox.

Popit is now changing that with POPIT INSIGHTS™, an extension to the company’s existing medication adherence platform already used by the world’s largest pharmaceutical companies, such as Novartis and Pfizer. The new solution offers a way to monitor how medication is being consumed, remind the patient if necessary, and gather study data remotely and in real time. On top of that the deployment is easy and quick.

The researchers were struggling with the same problems we already had a tool for.

Teemu Piirainen, Popit’s CEO explains further: “The company and our initial product were created on the foundation that we want to make medication connected. When the COVID situation escalated, we started to think of ways to refine our existing solution already used by pharma to serve the research community as well. The researchers were struggling with the same problems we already had a tool for: how to get the patient to take medications better and a sophisticated way to remotely and securely get data on if the medication was taken or not.”

First partners who sign up get the tools at a zero cost.

“It just seemed like something we had to build. And now it’s available. Anyone who is starting a medication study right now should get in touch with us. We want to contribute and the first partners who sign up get the tools at a zero cost. This is our way of pitching in and we’re already starting on different continents”, continues Piirainen.

Important request

While in some parts of the world the pandemic is starting to be more controllable, Popit requests to take extra care not to miss personal medications at this time, as up to 10% of hospitalizations are due to missing regular doses3. The admissions resulting from this poor adherence cause needless burden on the already heavily strained healthcare system. Medication can only work if it’s taken.

 

About Popit:

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitizing medication, a major opportunity that offers benefits for patients, healthcare payors and pharmaceutical companies. Popit works with the world’s leading pharmaceutical companies.

Media contact: Timo Heikkilä, Co-founder

Email: timo popit io

Web: https://popit.io/popit-adherence-kit-for-medication-research/

Twitter: https://twitter.com/popitmed

Facebook: https://www.facebook.com/popitmed

LinkedIn: https://www.linkedin.com/company/popit-ltd/

Instagram: https://www.instagram.com/popitmed

 

References:

1. https://covid-trials.com/
2. Osterberg L, Blaschke T. N Engl J Med. 2005;353:487–97
3. https://www.ncbi.nlm.nih.gov/pubmed/29666309

Seedi Solutions Agency invests in Popit

Finnish startup company Popit has received a significant investment from corporate management consulting firm Seedi Solutions Agency. Popit has previously raised funding from Butterfly Ventures, business angels and Business Finland.

Novartis And Popit Enter Into International Collaboration Agreement

The Finnish startup’s platform can improve medication adherence and help engage
patients by using innovative technology

HELSINKI, FINLAND, NOVEMBER 20, 2019

The pharmaceutical company Novartis and Finnish MedTech startup Popit have entered into an international collaboration agreement. The goal of Popit’s patient support solution to improve patient adherence and engagement. Popit’s mobile app tracks medication use through the innovative Popit Sense device, which easily clips onto a blister sheet of tablets. The startup’s cloud service sends bespoke messages to patients based on their medication habits, and in clinical trial use can collect real-time data.

Novartis, as a global healthcare company, is part of an ecosystem where digitalization is advancing fast. Collaboration with innovative health technology startups such as Popit enables new ways to provide patients with effective care faster, and more efficiently for the society. At the same time, innovation in the health sector supports economic growth and creates more exports and jobs in Finland and Europe.

Novartis has also entered into a collaboration with another Finnish startup, Precordior, to further develop heart disease detection using smart phones.

Medications are often missed

Only 30-50% of medication for chronic conditions are taken as prescribed. (1, 2)

“Medication nonadherence is a major issue in treatment of patients. Better treatment outcomes could be achieved, if medication was taken as prescribed. As a pharmaceutical company, it is very important for Novartis that the patients benefit from their medication in the best possible way, and Popit’s solution can potentially help with this,” says Antti Viitanen, Managing Director of Novartis Finland Oy. The first pilots on Popit’s technology are starting during 2019 with a focus on neurology in a number of European countries.

When the device manufactured by Popit is attached onto a medication blister, its sensors automatically detect when a tablet is taken. This information is sent to the app and to the cloud. If the tablet is not taken on time, the app reminds the patient. The intelligent cloud service automatically sends support messages based on medication consumption.

”The strength of our solution is its applicability for all kinds of medication blisters, which are the dominant form of packaging for solid drugs globally. At the same time, it does not require any changes to the packaging. It is unlike other products on the market,” says Teemu Piirainen, Popit’s CEO.

”The smart reminders and support messages have been designed to help and engage the patient during the treatment. Additionally, the technology makes it possible to gather real-time data for example in clinical trials. We are making medication connected and basically extending the Internet of Things to pills,” continues Piirainen.

Data and digital technologies can advance new treatment development

”It is in everyone’s best interest that the right patient is given the right treatment at the right time. This requires fast identification of symptoms, but also patient’s commitment to treatment,” says Antti Viitanen.

New technologies and digitalization make the development of new operational models possible. Currently, more health data is being collected and used than ever before. Utilizing it has become part of disease prevention, but it may help providing more targeted treatment to the right patients faster.

”The collaboration between Novartis and Popit is an example of how a small company from the superb Finnish startup scene can scale up to a global level with the help of an international partner. Also, the Finnish health sector growth strategy has been key in creating an ecosystem where innovations like this can thrive and increase wellbeing,” says Antti Viitanen. ”The global collaboration between Novartis and Popit stems from last year, when a group of Finnish startups together with Business Finland and the Finnish Ministry of Social Affairs and Health visited Novartis’ head office in Basel.”

About Popit

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitizing medicine, a major opportunity that offers benefits for patients, healthcare payors and pharmaceutical companies. Popit works with the world’s leading pharmaceutical companies, like Novartis and Pfizer. Find out more at www.popit.io

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com

Media contact: Timo Heikkilä, Co-founder
Twitter: https://twitter.com/popitmed
Facebook: https://www.facebook.com/popitmed
LinkedIn: https://www.linkedin.com/company/popit-ltd
Instagram: https://www.instagram.com/popitmed

References:

  1. https://jamanetwork.com/journals/jama/article-abstract/1690707
  2. https://www.who.int/chp/knowledge/publications/adherence_full_report.pdf

Study Shows Popit Reduces Number of Missed Pills By Over 80%

Results from a clinical study highlight a significant medication adherence improvement in patients using a novel reminder solution, consisting of a pill tracker and an app. The pill reminder solution was able to reduce number of missed pills by over 80%.

Popit Raises €1.2M Seed Financing To Quantify Medication

Butterfly Ventures as the lead investor, funding used for bringing product to market

Helsinki, Finland, August 23rd 2017Popit, a Finnish startup focusing on medical technology solutions, has raised over €1.2M ($1.4M) in seed financing. The capital was raised from Butterfly Ventures with participation from six private investors and Tekes, the Finnish Funding Agency for Innovation. The funding consists of an investment and a loan, and will be used for bringing the pioneering device Popit Sense to market.

Popit Sense

Popit Sense

Popit Sense tackles medical adherence, a problem that needlessly burdens the healthcare system and leads to lives lost. The small easy-to-use device attaches to a regular pill sheet where it automatically detects with patented technology when a pill has been popped. This information is sent onto a free app that supports the treatment by tracking medication effectiveness, remaining pills and medication usage patterns. It also reminds the user or a loved one if a pill has been forgotten.

Teemu Piirainen, Popit’s CEO: “The investment will enable us to pursue our vision of quantifying medication. Like step counters track activity, we track pills and support the patient in staying on track with medical treatment. This kind of technology hasn’t been available before and it opens up exciting new possibilities. For example, caregivers to their parents will be able to see from the mobile phone if mom or dad has taken the medication. Likewise, patients will be able to see how taking medication has had an impact on wellbeing.”

Juho Risku, co-founder and partner at Butterfly Ventures explains why they invested in Popit: “The cost impact of patients not taking pills that come in blister packs is well over 100 billion dollars annually. Vast majority of these costs could be avoided by improving medication adherence. Popit’s product tackles the problem in an intuitive way. The team has done excellent and systematic work in unraveling this complex issue and I firmly believe Popit is going to take a significant share of the adherence market.

The solution will be first available for the 100 million birth control pill users. For this purpose Popit is preparing to launch a crowdfunding campaign in November. The company also sees tremendous untapped opportunity in supporting patients on chronic disease medications, where a staggering 50% of patients are not taking their medications as prescribed.

The smart pill reminder solution will be available in Q2 2018.

About Popit:

Popit is a pioneer in improving patient adherence through smart consumer devices. The Company is dedicated to improving adherence by digitizing medicine, a major opportunity that offers benefits for pharmaceutical companies and consumers alike. Popit is planning to expand support to other major medication groups like hypertension, cholesterol, type 2 diabetes and migraine pills, which combined have an addressable market of over 1 billion users. For more information like videos and product images, please visit popit.io.

Media contact:  Teemu Piirainen, CEO
Phone: +358 44 222 6666
Email: teemu ät popit.io
Web: popit.io
Twitter: https://twitter.com/popitmed
Facebook: https://www.facebook.com/popitmed
Youtube: Popit Smart Pill Reminder

Popit Among Top-5 in EU eHealth Competition

Popit has qualified to be among the top-5 startups in this year’s EU eHealth Competition. The competition is held in Barcelona in conjunction with the Health2.0 event.

“Europe is currently a hotbed for digital health innovation and getting to the finals past all the competition was very difficult! Popit has an innovative solution with major impact, both of which were key criteria for the jury when deciding finalists”, says Teemu Piirainen, CEO of Popit.

The competition winners will be announced on May 3rd.

Related articles

Birth control pill is 99% effective in the perfect use BUT only 91% in a typical use. Read this article to understand why sometimes pills fail
Birth control pill is 99% effective in the perfect use BUT only 91% in a typical use. Read this article to understand why sometimes pills fail

Popit participated in the unique Tahko Ski Lift Pitch event on April 21st 2017

Popit participated in the unique Tahko Ski Lift Pitch event on April 21st. The competition was arranged at the Tahko ski resort and started off with a 3 minute pitch battle, taking place on a ski lift. Coming out victorious from the 1st round, we made it into the finals and eventually the top-6 out of 30 great startups.

M.D. Janne Sahlman, Popit’s Chief Medical officer and co-founder sheds some light into the intricacies of the competition: “It was a welcome change to pitch outdoors! It is always a challenge to describe our disruptive solution in a brief manner, but having no slides made it especially interesting. The positive feedback and recognition pushes us forward.”

blank

The Finnish National Broadcaster YLE also was there. You can see a clip here: http://areena.yle.fi/1-4121072 (Popit appears at 0:31).